ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Ocular Therapeutix Inc

Ocular Therapeutix Inc (OCUL)

9,64
0,17
(1,80%)
Geschlossen 05 Juli 10:00PM
9,5313
-0,1087
(-1,13%)
Nach Börsenschluss: 1:59AM

Ocular Therapeutix Inc (OCUL) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
9,5313
( 0,65% )
Gebot
9,47
Fragen
9,72
Volumen
1.834.129
9,41 Tagesbereich 9,74
6,2301 52-Wochen-Bereich 16,44
Marktkapitalisierung
Handelsende
9,47
Handelsbeginn
9,56
Letzter Handelszeitpunkt
Finanzvolumen
US$ 17.572.713
VWAP
9,581
Durchschnittliches Volumen (3 Mio.)
US$ 3.073.602
Ausgegebene Aktien
218.960.358
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-6,54
Gewinn pro Aktie (EPS)
-1,45
Erlöse (LTM)
52,04M
Nettogewinn (LTM)
-290,5M

Über Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthal... Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Bedford, United States
Gegründet
2026
Ocular Therapeutix Inc is listed in the Healthcare sector of the NASDAQ with ticker OCUL. The last closing price for Ocular Therapeutix was US$9,47. Over the last year, Ocular Therapeutix shares have traded in a share price range of US$ 6,2301 to US$ 16,44.

Ocular Therapeutix currently has 218.960.358 shares in issue. The market capitalisation of Ocular Therapeutix is US$2,09 billion. Ocular Therapeutix has a price to earnings ratio (PE ratio) of -6.54.

OCUL Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.2587-2.642492339129.7910.249.434108219.78656929CS
41.031312.13294117658.510.6158.07132248319.4151238CS
121.161313.87455197138.3710.6157.8630101549.21425816CS
26-2.5487-21.098509933812.0813.036.230146556399.20440009CS
520.34133.713819368889.1916.446.2301369539910.37745119CS
1564.391385.43385214015.1416.441.99522563748.8436067CS
260-4.8387-33.672233820514.3716.441.99517229128.24019379CS

OCUL - Frequently Asked Questions (FAQ)

What is the current Ocular Therapeutix Inc share price?
The current share price of Ocular Therapeutix Inc is US$ 9,5313
How many Ocular Therapeutix Inc shares are in issue?
Ocular Therapeutix Inc has 218.960.358 shares in issue
What is the market cap of Ocular Therapeutix Inc?
The market capitalisation of Ocular Therapeutix Inc is USD 2,09B
What is the 1 year trading range for Ocular Therapeutix Inc share price?
Ocular Therapeutix Inc has traded in the range of US$ 6,2301 to US$ 16,44 during the past year
What is the PE ratio of Ocular Therapeutix Inc?
The price to earnings ratio of Ocular Therapeutix Inc is -6,54
What is the cash to sales ratio of Ocular Therapeutix Inc?
The cash to sales ratio of Ocular Therapeutix Inc is 39,85
What is the registered address of Ocular Therapeutix Inc?
The registered address for Ocular Therapeutix Inc is 14 Crosby Drive, Bedford, Massachusetts, 01730
What is the Ocular Therapeutix Inc website address?
The website address for Ocular Therapeutix Inc is www.ocutx.com
Which industry sector does Ocular Therapeutix Inc operate in?
Ocular Therapeutix Inc operates in the Biotechnology & Life Sciences sector

OCUL Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen